Advent Healthcare Buyout Offer
Advent International Proposes Going-Private Acquisition of Definitive Healthcare for $1.02 Per Share
Anonymous
Key Points
1
Advent directly holds 62,493,676 Definitive Healthcare Class A shares, representing 58.54% of the Class A stock, held across multiple Advent funds. Ownership size gives Advent potential for governance changes, including director-nomination rights of two directors when its stake is at or above 21.5%, and one director if remaining above 5%.
2
Definitive Healthcare’s special committee is advised by Rothschild & Co as financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP as legal counsel; the company itself is advised by Evercore as financial advisor and Hogan Lovells Cadwalader as legal counsel.
3
Clay Ritchey will become Definitive Healthcare’s CEO on September 8, 2026; he previously served as CEO of Verato and has held senior leadership roles at Evariant, Imprivata, and Equinox Healthcare.
4
Market reaction to Advent’s approach included a roughly 14% premarket jump to about $1.03 per share in response to the news.
Advent International has offered to take Definitive Healthcare private at $1.02 per share in an all-cash deal. Kalkine Media reported that Advent already owns 58.54% of the company and is now seeking to buy the remaining shares. A special committee of independent directors is reviewing the non-binding offer.
The healthcare data company's stock jumped about 14% in premarket trading on the news. MarketWatch noted that Definitive Healthcare said no action is required and there is no guarantee the deal will close. The company also announced Clay Ritchey will become CEO on September 8, 2026.
Advent's Growing Control and Governance Rights
Advent International holds 62.5 million Class A shares across multiple funds, giving it 58.54% ownership of Definitive Healthcare. Kalkine Media explained this stake size grants Advent the right to nominate two board directors. This level of control positions Advent to shape company decisions and strategic direction without a majority vote.
The private equity firm has signaled plans to explore structural changes including a potential delisting from NASDAQ. TradingView reported that founder Jason Krant is expected to roll over part of his stake into the new deal. Advent's ownership already exceeds typical thresholds for activist intervention in corporate governance.
How the Deal Review Process Will Work
Definitive Healthcare's special committee is advised by Rothschild & Co as financial advisor and law firm Skadden, Arps, Slate, Meagher & Flom. CityBiz noted the company itself is advised by Evercore and Hogan Lovells Cadwalader. These advisors will evaluate Advent's $1.02-per-share offer against other potential alternatives.
The special committee faces pressure to maximize shareholder value while weighing the certainty of Advent's offer against uncertain higher bids. No timeline for the decision has been announced. Definitive Healthcare emphasized that shareholders need not take action at this stage.
New Leadership Arrives as Deal Talks Begin
Clay Ritchey will take over as CEO on September 8, 2026, replacing Kevin Coop. Kalkine Media noted that Ritchey previously led Verato and held senior roles at Evariant, Imprivata, and Equinox Healthcare. His appointment suggests Definitive Healthcare is preparing for leadership changes amid the going-private proposal.
Ritchey's background in healthcare IT and data companies aligns with Definitive Healthcare's core business. The timing of his appointment during acquisition talks raises questions about his role in any merged entity. His leadership track record may influence how the special committee evaluates the deal's strategic merit.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
17
Reach
29
A
AnonymousAuthor
